Orthocell CEO and Managing Director Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients.
Orthocell CEO and Managing Director, Paul Anderson, spoke with Ticker News about the positive findings from our CelGro™ clinical study.
Orthocell has been featured in The Market Herald, following the announcement of clinical data from the CelGro nerve regeneration trial demonstrating the potential to return function to paralysed upper limbs following 12 months of treatment Read the article HERE.
Orthocell has been featured in The Market Herald, following our announcement of patents granted in China and New Zealand for CelGro. Read the article HERE.
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive following the announcement newly granted patents for its CelGro™ collagen rope in China and Hong Kong.
Orthocell has been featured in The Market Herald, following our announcement of granted patents in China and Hong Kong for its novel CelGro collagen rope device for ACL repairs.
Orthocell has been featured in The Market Herald, following the announcement of a newly granted U.S. divisional patent for CelGro. Read the article HERE.
BioWorld has reported on Orthocell’s rising share price, following the U.S. approval for our collagen medical device for dental guided bone and soft tissue regeneration applications.
Orthocell’s Striate+™ has been featured in Bite Magazine, highlighting its effectiveness for dental bone defect repair and tissue augmentation around dental implants.
Orthocell CEO Paul Anderson spoke to BioWorld, following marketing clearance from Australia’s Therapeutic Goods Administration (TGA) for our Celgro™ collagen medical device for dental guided bone and soft tissue regeneration applications.